Ownership & Insider Lab

Look up a company to review current SEC-traceable insider positions, exact reporting-owner relationships across other published companies, a dated chronology of the published ownership evidence, and recent supported insider transactions where transaction history is separately available.
Coverage follows the existing reviewed company dataset and fails closed when a ticker is not currently supported.

UNITED THERAPEUTICS Corp (UTHR)

Nasdaq · SEC CIK 0001082554

$28.73MCovered current disclosed holdings
4Covered reporting owners
4Covered direct positions
4Source ownership filings

This is the supported SEC-traceable subset, not total insider ownership or personal wealth. Values reflect the current disclosed positions Grizzly Bulls can resolve and value. Latest source filing: Sep 18, 2026 · values through Sep 25, 2026.

Covered reporting owners

Filter the reporting-owner snapshot by holder, role, or security. Position values are shown only where the current reviewed data supports them.

4 shown
HolderRolePositionCurrent valueLatest filing
Martine A. RothblattResearch disclosed relationshipsChairperson & CEO · Director40,513 sharesCommon Stock, par value $0.01 per share$19.26MSep 18, 2026
Ray KurzweilResearch disclosed relationshipsDirector13,320 sharesCommon Stock, par value $0.01 per share$6.33MJul 23, 2026
Christopher CauseyResearch disclosed relationshipsDirector4,190 sharesCommon Stock, par value $0.01 per share$1.99MJul 23, 2026
Christopher PatuskyResearch disclosed relationshipsDirector2,410 sharesCommon Stock, par value $0.01 per share$1.15MJul 23, 2026

Reporting-owner research graph

These relationships are joined only when the same single SEC reporting-owner CIK appears unambiguously across the publication-authorized company ownership universe. Name similarity is never used to create a relationship.

This graph is bounded to the company ownership relationships currently published by Grizzly Bulls. It is not a complete employment, board, ownership, portfolio, or wealth history, and a missing relationship does not establish that none exists.

SEC transaction evidence ledger

Each row preserves the reviewed SEC transaction evidence, including the effective-date basis, amendment state, reported post-transaction position when present, and a separately published current covered owner/security position when one can be matched uniquely. Reported price is shown when present. The lab does not calculate gross proceeds, reconstruct balances between filings, or treat historical transactions as current wealth.

12 shown
Effective dateHolderActionSecurityUnitsReported priceReported position after transactionCurrent covered positionFiling
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share40 shares$534.0940,513 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share160 shares$533.217540,553 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share800 shares$532.059340,713 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share278 shares$530.967841,513 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share120 shares$529.663341,791 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share40 shares$527.5541,911 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share80 shares$525.42541,951 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share120 shares$523.973342,031 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share80 shares$521.8242,151 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 15, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsAcquisitionSEC code MCommon Stock, par value $0.01 per share1,718 shares$135.4242,231 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 16, 2026
Jul 14, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share200 shares$532.60240,513 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 15, 2026
Jul 14, 2026Transaction dateMartine A. RothblattResearch disclosed relationshipsSaleSEC code SCommon Stock, par value $0.01 per share107 shares$531.081140,713 shares40,513 sharesOwner coverage latest filing Sep 18, 20264Filed Jul 15, 2026

A reported post-transaction position is the balance stated in that historical transaction filing. A current covered position is a separate latest owner/security observation and may reflect later filings or activity. They are shown side by side as evidence points, not as a reconstructed continuous ledger.

Published 12 of 50 source candidates under the current reviewed security-resolution rules.

Covered securities

SecurityInstrument familyCovered positionsCovered value
Common Stock, par value $0.01 per shareordinary-share4$28.73M

Coverage and interpretation

Current holdings: direct positions that the reviewed ownership data can trace to an exact reporting owner, legal security, and current-basis quantity.

Current value: the existing published company-position valuation. This lab does not recalculate security values or infer missing positions.

Transaction evidence: historical flow observations with filing provenance. Reported post-transaction balances and current covered positions are separate evidence points; the lab does not interpolate ownership between them.

Reporting-owner graph: exact reporting-owner CIK relationships across the published company universe. It does not merge people by name or create a complete personal history.

Not included here: a claim of total insider ownership, total personal wealth, institutional 13F ownership, a transaction-value estimate, an insider sentiment score, or an investment recommendation.

Published ownership evidence chronology

This sequence orders only the ownership evidence already published by Grizzly Bulls for the exact reporting-owner relationships above. Transaction rows are ordered by filing date while preserving the separate economic effective date and its basis. Current covered snapshots remain separate latest observations.

The chronology does not interpolate ownership between entries, infer missing activity, pair an amended filing with an assumed parent, infer amendment supersession, or treat a current covered snapshot as proof of continuous ownership.

Christopher Causey

SEC reporting-owner CIK 0001237334 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Jul 23, 2026Latest represented filing dateUNITED THERAPEUTICS Corp (UTHR)NasdaqCurrent covered snapshotDirectorValuation observation Sep 25, 2026Common Stock, par value $0.01 per share: 4,190 sharesCurrent covered company value: $1.99MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 0 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Christopher Patusky

SEC reporting-owner CIK 0001231427 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Jul 23, 2026Latest represented filing dateUNITED THERAPEUTICS Corp (UTHR)NasdaqCurrent covered snapshotDirectorValuation observation Sep 25, 2026Common Stock, par value $0.01 per share: 2,410 sharesCurrent covered company value: $1.15MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 0 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Martine A. Rothblatt

SEC reporting-owner CIK 0001106578 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Sep 18, 2026Latest represented filing dateUNITED THERAPEUTICS Corp (UTHR)NasdaqCurrent covered snapshotChairperson & CEO · DirectorValuation observation Sep 25, 2026Common Stock, par value $0.01 per share: 40,513 sharesCurrent covered company value: $19.26MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqAcquisitionSEC code MEffective Jul 15, 2026 · transaction dateReported units 1,718 shares · reported price 135.42Common Stock, par value $0.01 per shareReported position after transaction: 42,231 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 80 shares · reported price 521.82Common Stock, par value $0.01 per shareReported position after transaction: 42,151 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 120 shares · reported price 523.9733Common Stock, par value $0.01 per shareReported position after transaction: 42,031 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 80 shares · reported price 525.425Common Stock, par value $0.01 per shareReported position after transaction: 41,951 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 40 shares · reported price 527.55Common Stock, par value $0.01 per shareReported position after transaction: 41,911 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 120 shares · reported price 529.6633Common Stock, par value $0.01 per shareReported position after transaction: 41,791 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 278 shares · reported price 530.9678Common Stock, par value $0.01 per shareReported position after transaction: 41,513 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 800 shares · reported price 532.0593Common Stock, par value $0.01 per shareReported position after transaction: 40,713 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 160 shares · reported price 533.2175Common Stock, par value $0.01 per shareReported position after transaction: 40,553 shares4 filing0001106578-26-000099
Jul 16, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 15, 2026 · transaction dateReported units 40 shares · reported price 534.09Common Stock, par value $0.01 per shareReported position after transaction: 40,513 shares4 filing0001106578-26-000099
Jul 15, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 14, 2026 · transaction dateReported units 107 shares · reported price 531.0811Common Stock, par value $0.01 per shareReported position after transaction: 40,713 shares4 filing0001106578-26-000098
Jul 15, 2026Filed dateUNITED THERAPEUTICS Corp (UTHR)NasdaqSaleSEC code SEffective Jul 14, 2026 · transaction dateReported units 200 shares · reported price 532.602Common Stock, par value $0.01 per shareReported position after transaction: 40,513 shares4 filing0001106578-26-000098

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 12 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Ray Kurzweil

SEC reporting-owner CIK 0001108501 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Jul 23, 2026Latest represented filing dateUNITED THERAPEUTICS Corp (UTHR)NasdaqCurrent covered snapshotDirectorValuation observation Sep 25, 2026Common Stock, par value $0.01 per share: 13,320 sharesCurrent covered company value: $6.33MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 0 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Continue this ownership research

These handoffs preserve the exact company identities already represented in the reporting-owner graph. My Stocks keeps a listed company in your existing research lists. Research Inbox is a separate company-change update workflow.

Saving a company to My Stocks never enables updates, and opening Research Inbox never subscribes you automatically. Each update remains an explicit company-level opt-in under the existing Research Inbox consent flow.

CompanyReporting-owner contextPublished evidenceContinue research
UNITED THERAPEUTICS Corp (UTHR)Nasdaq · Current company16Published chronology observationsLatest represented evidence Sep 18, 2026

These are company-level continuation paths, not reporting-owner subscriptions. Saving or watching one company does not automatically save or watch the other companies connected to the same reporting owner, and it does not create an owner-level alert.